从每周一次到每周两次全前列腺立体定向放疗联合局灶推量:多中心II期hypo-FLAME 2.0试验主要终点分析
hypo-FLAME 2.0多中心II期试验纳入124例中高危前列腺癌患者,采用每周两次方案行全前列腺35 Gy/5次立体定向放疗并同步局灶推量至50 Gy。90天2级泌尿生殖毒性和胃肠道毒性累积发生率分别为47.5%和7.4%,未观察到≥3级毒性。与既往每周一次方案(n=100)相比,每周两次组2级泌尿生殖毒性更高(47.5% vs 34.0%,p=0.01),急性肠道和泌尿生活质量更差。
要点
- 每周两次全前列腺35 Gy/5次SBRT联合局灶推量至50 Gy,未观察到≥3级泌尿生殖或胃肠道毒性。
- 90天2级泌尿生殖毒性和胃肠道毒性累积发生率分别为47.5%和7.4%。
- 与每周一次方案相比,每周两次组2级泌尿生殖毒性更高(47.5% vs 34.0%,p=0.01),急性肠道和泌尿生活质量更差。
核心结论
- 每周两次前列腺SBRT联合等毒性局灶推量具有可接受的急性泌尿生殖和胃肠道毒性。
- 基于每周一次与每周两次方案的比较,应告知患者疗程更长方案的短期优势。
研究设计与样本
- 多中心II期hypo-FLAME 2.0试验,纳入中高危前列腺癌患者,全前列腺SBRT 35 Gy/5次,局灶推量至50 Gy,每周两次方案。
- 主要终点为放射性急性毒性(CTCAE v5.0),并评估生活质量最小临床重要变化比例。
- 将每周两次方案的急性毒性和生活质量与既往每周一次hypo-FLAME方案(n=100)进行比较。
- 2020年8月至2022年2月共入组124例患者并接受每周两次治疗。
- 注册号ClinicalTrials.gov:NCT04045717。
主要发现
- 未观察到≥3级泌尿生殖或胃肠道毒性。
- 90天2级泌尿生殖毒性累积发生率为47.5%,2级胃肠道毒性累积发生率为7.4%。
- 每周一次组2级泌尿生殖毒性显著更少(34.0% vs 每周两次组47.5%,p=0.01)。
- 急性胃肠道毒性未见显著差异。
- 每周一次组急性肠道和泌尿生活质量更优。
临床怎么用
- 基于每周一次与每周两次方案的比较,应告知患者疗程更长方案的短期优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The hypo-FLAME trial showed that once-weekly (QW) focal boosted prostate stereotactic body radiotherapy (SBRT) is associated with acceptable acute genitourinary (GU) and gastrointestinal (GI) toxicity. Currently, we investigated the safety of reducing the overall treatment time (OTT) of focal boosted prostate SBRT from 29 to 15 days. MATERIAL AND METHODS: Patients with intermediate- and high-risk prostate cancer were treated with SBRT delivering 35 Gy in 5 fractions to the whole prostate gland with an iso-toxic boost up to 50 Gy to the intraprostatic lesion(s) in a semi-weekly (BIW) schedule. The primary endpoint was radiation-induced acute toxicity (CTCAE v5.0). Changes in quality of life (QoL) were examined in terms of proportions achieving a minimal clinically important change (MCIC). Finally, acute toxicity and QoL scores of the BIW schedule were compared with the results of the prior QW hypo-FLAME schedule (n = 100). RESULTS: Between August 2020 and February 2022, 124 patients were enrolled and treated BIW. No grade ≥3 GU or GI toxicity was observed. The 90-days cumulative incidence of grade 2 GU and GI toxicity rates were 47.5% and 7.4%, respectively. Patients treated QW scored significant less grade 2 GU toxicity (34.0%, p = 0.01). No significant differences in acute GI toxicity were observed. Furthermore, patients treated QW had a superior acute bowel and urinary QoL. CONCLUSION: Semi-weekly prostate SBRT with iso-toxic focal boosting is associated with acceptable acute GU and GI toxicity. Based on the comparison between the QW and BIW schedule, patients should be counselled regarding the short-term advantages of a more protracted schedule. Registration number ClinicalTrials.gov: NCT04045717.
引用
- De Cock L, Draulans C, Pos FJ, et al. From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Radiother Oncol. 2023. PMID: 37178932. doi:10.1016/j.radonc.2023.109713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。